1

2
Tarran Jones
Tsuchiya Masayuki, Sato Koh, Bendig Mary Margaret, Jones Steven Tarran, Saldanha Jose William: Reconstituted human antibody against human interleukin 6 receptor.. Chugai Pharmaceutical, December 14, 1994: EP0628639-A1 (54 worldwide citation)

A reconstituted human antibody against a human interleukin 6 receptor (IL-6R), which is composed of: (A) an L chain composed of (1) the C region of a human L chain and (2) the V region of an L chain comprising the framework region (FR) of a human L chain and the complementarity-determining region (C ...


3
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, February 19, 2008: US07332582 (21 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration t ...


4
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, July 19, 2011: US07981416 (9 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect ...


5
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Human immunomodulatory monoclonal antibodies for the treatment of cancer. CureTech, Mor Research Application, Winston & Strawn, April 28, 2009: US07524498 (7 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect ...


6
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, BioTechnology Law Group, Daniel M Chambers, November 9, 2010: US07829674 (4 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


7
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Williams: Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08025877 (2 worldwide citation)

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


8

9
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08026342 (1 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


10
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, July 17, 2012: US08222373

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...